Diagnosis and management of alcoholic liver disease

Journal of Clinical and Translational Hepatology

Volumn 3, Issue 2, 2015, Pages 109-116

  Dugum, Mohannad ^a   McCullough, Arthur ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alcoholic cirrhosis; Alcoholic hepatitis; Alcoholism; Liver transplantation

Indexed keywords

EID: 84989234630     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2015.00008     Document Type: Review

References (51)

1. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol 2013;59:160–168. doi: 10.1016/j.jhep.2013.03.007.
2. Kamper-Jorgensen M, Gronbaek M, Tolstrup J, Becker U. Alcohol and cirrhosis: Dose–response or threshold effect? J Hepatol 2004;41:25–30. doi:10.1016/j. jhep.2004.03.002.
3. Gao B, Bataller R. Alcoholic liver disease: Pathogenesis and new therapeutic targets. Gastroenterology 2011;141:1572–1585. doi: 10.1053/j.gastro. 2011.09.002.
4. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257–265. doi: 10.1016/S0168-8278(02)00413-0.
5. Sato N, Lindros KO, Baraona E, Ikejima K, Mezey E, Jarvelainen HA, et al. Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res 2001;25:40S– 45S. doi: 10.1111/j.1530-0277.2001.tb02371.x.
6. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995;346:987–990.
7. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143:1179-1187,e1-e3. doi: 10.1053/j.gastro.2012.08.002.
8. Chiang DJ, McCullough AJ. The impact of obesity and metabolic syndrome on alcoholic liver disease. Clin Liver Dis 2014;18:157–163. doi:10.1016/j.cld. 2013.09.006.
9. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut 2014;63:844–855. doi: 10.1136/gutjnl-2013-306627.
10. Grant BF. Barriers to alcoholism treatment: Reasons for not seeking treatment in a general population sample. J Stud Alcohol 1997;58:365–371. doi: 10. 15288/jsa.1997.58.365.
11. McKnight-Eily LR, Liu Y, Brewer RD, Kanny D, Lu H, Denny CH, et al. Vital signs: Communication between health professionals and their patients about alcohol use–44 states and the District of Columbia, 2011. MMWR Morb Mortal Wkly Rep 2014;63:16–22.
12. Aertgeerts B, Buntinx F, Kester A. The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: A diagnostic meta-analysis. J Clin Epidemiol 2004;57:30–39. doi: 10.1016/S08954356(03)00254-3.
13. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction 1993;88:791–804. doi: 10.1111/j.1360-0443.1993.tb02093.x.
14. Hock B, Schwarz M, Domke I, Grunert VP, Wuertemberger M, Schiemann U, et al. Validity of carbohydrate-deficient transferrin (%CDT), gammaglutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: A study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction 2005;100:1477–1486. doi: 10.1111/j.1360-0443.2005.01216.x.
15. Bell H, Tallaksen CM, Try K, Haug E. Carbohydrate-deficient transferrin and other markers of high alcohol consumption: A study of 502 patients admitted consecutively to a medical department. Alcohol Clin Exp Res 1994;18:1103– 1108. doi: 10.1111/j.1530-0277.1994.tb00088.x.
16. Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol 2004;39: 336–339. doi:10.1093/alcalc/agh074.
17. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500. doi: 10.1056/NEJM200102153440706.
18. Mueller S, Seitz HK, Rausch V. Non-invasive diagnosis of alcoholic liver disease. World J Gastroenterol 2014;20:14626–14641. doi: 10.3748/wjg.v20. i40.14626.
19. Naveau S, Gaude G, Asnacios A, Agostini H, Abella A, Barri-Ova N, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009;49:97–105. doi: 10. 1002/hep.22576.
20. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005;3:167–174. doi: 10. 1016/S1542-3565(04)00625-1.
21. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373–1381. doi: 10.1002/hep.20935.
22. Sandrin L, Tanter M, Gennisson JL, Catheline S, Fink M. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2002;49:436-446.
23. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography(FibroScan): A prospective study. Gut 2006;55:403-408. doi:10.1136/gut.2005.069153.
24. Nahon P, Kettaneh A, Tengher-Barna I, Ziol M, de Ledinghen V, Douvin C, et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008;49:1062-1068. doi: 10.1016/j.jhep. 2008.08.011.
25. Mueller S, Millonig G, Sarovska L, Friedrich S, Reimann FM, Pritsch M, et al. Increased liver stiffness in alcoholic liver disease: Differentiating fibrosis from steatohepatitis. World J Gastroenterol 2010;16:966–972. doi:10.3748/wjg. v16.i8.966.
26. Diehl AM. Alcoholic liver disease: Natural history. Liver Transpl Surg 1997;3: 206–211.
27. Luca A, Garcia-Pagan JC, Bosch J, Feu F, Caballeria J, Groszmann RJ, et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997;112:1284–1289.
28. Xie YD, Feng B, Gao Y, Wei L. Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: A systematic review and meta-analysis. Hepatol Res 2013. doi: 10.1111/hepr.12131.
29. O'Shea RS, Dasarathy S, McCullough AJ. Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010;51:307–328. doi: 10.1002/hep.23258.
30. Mayo-Smith MF, Beecher LH, Fischer TL, Gorelick DA, Guillaume JL, Hill A, et al. Management of alcohol withdrawal delirium: an evidence-based practice guideline. Arch Intern Med 2004;164:1405–1412. doi:10.1001/archinte.164. 13.1405.
31. Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1106–1117. doi:10.1016/j.pnpbp.2007.09.021.
32. Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol 1997;58:7-29. doi: 10. 15288/jsa.1997.58.7.
33. European Association for the Study of Liver. EASL clinical practical guidelines: Management of alcoholic liver disease. J Hepatol. 2012;57:399-420. doi: 10. 1016/j.jhep.2012.04.004.
34. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193– 199.
35. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005;41:353–358. doi: 10.1002/hep.20503.
36. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007;45:1348–1354. doi: 10. 1002/hep.21607.
37. Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: Early response to therapy is the key factor. Gastroenterology 2009;137:541– 548. doi: 10.1053/j.gastro.2009.04.062.
38. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: Glucocorticosteroids for alcoholic hepatitis–a cochrane hepato-biliary group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008;27: 1167–1178. doi: 10.1111/j.1365-2036.2008.03685.x.
39. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A doubleblind, placebo-controlled trial. Gastroenterology 2000;119:1637–1648.
40. Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thevenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008;48:465–470. doi: 10. 1016/j.jhep.2007.10.010.
41. N'Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006;4:1062–1068. doi:10. 1016/j.cgh.2006.05.013.
42. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the united states. Gastroenterology 2011;141:1249–1253. doi: 10. 1053/j.gastro.2011.06.061.
43. Burra P, Senzolo M, Adam R, Delvart V, Karam V, Germani G, et al. Liver transplantation for alcoholic liver disease in europe: A study from the ELTR (european liver transplant registry). Am J Transplant 2010;10:138–148. doi: 10. 1111/j.1600-6143.2009.02869.
44. Murray KF, Carithers RL Jr. AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005;41:1407–1432. doi: 10.1002/hep.20704.
45. Tang H, Boulton R, Gunson B, Hubscher S, Neuberger J. Patterns of alcohol consumption after liver transplantation. Gut 1998;43:140–145. doi:10. 1136/gut.43.1.140.
46. Singal AK, Duchini A. Liver transplantation in acute alcoholic hepatitis: Current status and future development. World J Hepatol 2011;3:215–218. doi: 10. 4254/wjh.v3.i8.215.
47. Singal AK, Bashar H, Anand BS, Jampana SC, Singal V, Kuo YF. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: Exploratory analysis from the UNOS database. Hepatology 2012;55:1398– 1405. doi: 10.1002/hep.25544.
48. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365: 1790–1800. doi: 10.1056/NEJMoa1105703.
49. Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54:900–909. doi: 10.1002/hep.24486.
50. Singal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: Current challenges and future directions. Clin Gastroenterol Hepatol 2014;12:555–564. doi: 10.1016/j.cgh.2013.06.013.
51. https://www.clinicaltrials.gov.